Discussion about this post

User's avatar
Md Nadim Ahmed's avatar

Do you think the NIH should use more innovative prizes or is that not an appropriate tool for the agency?

Expand full comment
Raghu Parthasarathy's avatar

Thanks for the interesting analysis, but I don't understand the logic here.

Claim: The NIH funds a lot of small, crappy trials

Data: The (Phase I) trial size is similar for NIH and for other funders

How does the data counter the claim? Couldn't one simply conclude that *every funder* funds too many small, crappy trials?

(I posted this comment on MR, as well.)

Expand full comment
9 more comments...

No posts